California Attorney General Rob Bonta remains steadfast in his legal action against two anti-abortion organizations that promote a controversial treatment known as "abortion pill reversal." In a lawsuit filed in 2023, Bonta accused Heartbeat International and RealOptions of making misleading claims about the efficacy and safety of high-dose progesterone therapy intended to counteract the effects of mifepristone, a medication used in medical abortions. The lawsuit also alleges the groups failed to adequately inform women about potential risks, including severe bleeding.

The case is being heard in Alameda County Superior Court, where after six weeks of testimony, both sides have concluded presenting evidence. Bonta expressed confidence that the court will rule in favor of the state, although no decision has yet been reached. Closing arguments are scheduled for September 17, with a ruling expected within 90 days.

Heartbeat International and RealOptions defend their position, asserting that women facing regret after taking an abortion pill should have the option to attempt to save their pregnancies. A recent example cited by the organizations involves Elizabeth Barrett, a Southern California woman who reportedly changed her mind shortly after taking the abortion pill and later gave birth to a healthy child after using services associated with Heartbeat International. The groups maintain that no woman should be compelled to continue with an abortion she no longer wishes to have.

The legal debate encompasses differing views on the scientific validity and ethical considerations of abortion pill reversal treatments. Attorneys representing the anti-abortion groups have challenged the credibility of the medical experts called by the Attorney General’s office, highlighting that one witness acknowledged having performed over 5,000 abortions during his medical career. Joe Barnas, counsel from the Thomas More Society representing Heartbeat International, argued that such testimony reflects an ideological stance favoring expanded abortion access, rather than a neutral scientific perspective.

The controversy underscores the broader and ongoing debate surrounding abortion access and reproductive rights in California. The court’s decision in this case could have significant implications for how abortion pill reversal therapies are regulated and communicated to women in the state.